Coherus Oncology, Inc.
CHRS
$1.59
$0.010.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 10.17% | 12.84% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.17% | 12.84% | |||
| Cost of Revenue | 8.71% | 9.60% | |||
| Gross Profit | 10.87% | 14.45% | |||
| SG&A Expenses | -7.98% | -12.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.13% | -3.47% | |||
| Operating Income | -2.48% | 7.15% | |||
| Income Before Tax | -4.11% | 0.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.11% | 0.77% | |||
| Earnings from Discontinued Operations | -3.14% | -97.38% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.94% | -111.93% | |||
| EBIT | -2.48% | 7.15% | |||
| EBITDA | -2.71% | 7.20% | |||
| EPS Basic | -2.29% | -111.92% | |||
| Normalized Basic EPS | 0.44% | 5.59% | |||
| EPS Diluted | -2.29% | -111.92% | |||
| Normalized Diluted EPS | 0.44% | 5.59% | |||
| Average Basic Shares Outstanding | 3.56% | 0.13% | |||
| Average Diluted Shares Outstanding | 3.56% | 0.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||